Journal article icon

Journal article

Effects of Bowman-Birk inhibitor concentrate (BBIC) in patients with benign prostatic hyperplasia.

Abstract:

BACKGROUND: The Bowman-Birk inhibitor is a soybean-derived protease inhibitor that has anti-inflammatory and anticarcinogenic activities. METHODS: A Phase I trial of Bowman-Birk inhibitor concentrate (BBIC) in 19 male subjects with benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS) has been performed. RESULTS: The results of the trial indicated that there was no dose-limiting toxicity of BBIC. There was a statistically significant decrease in serum PSA levels in all BB...

Expand abstract
Publication status:
Published

Actions


Access Document


Publisher copy:
10.1002/pros.1077

Authors


More by this author
Institution:
University of Oxford
Division:
MSD
Department:
Oncology
Role:
Author
Expand authors...
Journal:
Prostate
Volume:
48
Issue:
1
Pages:
16-28
Publication date:
2001-06-01
DOI:
EISSN:
1097-0045
ISSN:
0270-4137
Source identifiers:
118180

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP